^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SAR444200

    i
    Other names: SAR444200
    Associations

    News

    Trials
    Company:
    Sanofi
    Drug class:
    TCR modulator, GPC-3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    5ms
    Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=106, Recruiting, Sanofi | Trial completion date: May 2030 --> Dec 2030 | Trial primary completion date: May 2030 --> Dec 2030
    Trial completion date • Trial primary completion date • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • GPC3 (Glypican 3)
    |
    GPC3 expression • GPC3 positive
    |
    Tecentriq (atezolizumab) • SAR444200
    10ms
    Phase I/II open-label study on an anti-GPC3 T cell engager, SAR444200, in patients with advanced solid tumors: Preliminary dose escalation results (ESMO 2023)
    Conclusions These preliminary results from the first two DLs suggest that SAR444200 is tolerable at the tested DLs in patients with advanced solid tumors. Dose escalation continues at this time.
    Clinical • P1/2 data • Metastases
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • GPC3 (Glypican 3)
    |
    GPC3 expression • GPC3 positive
    |
    SAR444200
    1year
    Dose Escalation and Expansion Study of SAR444200 in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=106, Recruiting, Sanofi | Trial completion date: May 2029 --> May 2030 | Trial primary completion date: May 2029 --> May 2030
    Trial completion date • Trial primary completion date • Metastases
    |
    GPC3 (Glypican 3)
    |
    GPC3 expression • GPC3 positive
    |
    Libtayo (cemiplimab-rwlc) • SAR444200
    over1year
    Dose Escalation and Expansion Study of SAR444200 in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=106, Recruiting, Sanofi | Trial completion date: Feb 2028 --> May 2029 | Trial primary completion date: Feb 2028 --> May 2029
    Trial completion date • Trial primary completion date
    |
    GPC3 (Glypican 3)
    |
    GPC3 expression • GPC3 positive
    |
    Libtayo (cemiplimab-rwlc) • SAR444200
    almost2years
    Dose Escalation and Expansion Study of SAR444200 in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=106, Recruiting, Sanofi | Not yet recruiting --> Recruiting
    Enrollment open
    |
    GPC3 (Glypican 3)
    |
    GPC3 expression • GPC3 positive
    |
    Libtayo (cemiplimab-rwlc) • SAR444200
    almost2years
    Dose Escalation and Expansion Study of SAR444200 in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=106, Not yet recruiting, Sanofi
    New P1/2 trial
    |
    GPC3 (Glypican 3)
    |
    GPC3 expression • GPC3 positive
    |
    Libtayo (cemiplimab-rwlc) • SAR444200